| ［1］Falzon D, Jaramillo E,Schünemann HJ,et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J, 2011, 38(3):516-528. ［2］Chiang CY,Centis R,Migliori GB. Drug-resistant tuberculosis: past, present, future. Respirology, 2010, 15(3):413-432. ［3］The Lancet Infections Diseases.The worldwide epidemic of multidrug-resistant tuberculosis. Lancet Infect Dis, 2011, 11(5):333.［4］World Health Organization (WHO). Medicines for tuberculosis［J/OL］.WHO Drug Information, 2006，20（4）：239-245. ［2011-05-05］.http://whqlibdoc.who.int/druginfo/20_4_2006.pdf. ［5］谭金哲，董景涛. 抗结核新药SQ109、PA-824、OPC-67683与R207910研究进展.中国抗生素杂志,2010,35(6):408-411.［6］Nuermberger E,Rosenthal I,Tyagi S,et al.Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother, 2006, 50(8):2621-2625.［7］高凌玉,周建琴,孙承航. 抗结核候选新药PA-824的研究进展.国外医药抗生素分册,2006,27(6):241-244.［8］TB Alliance. TB alliance launchers first clinical trial of a novel tb drug regimen ［R/OL］(2010-11-08)［2011-05-05］.http://www.tballiance.org/newscenterr/view-brief.php?id=942.［9］Andries K,Verhasselt P,Guillemont J,et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307(5707):223-227.［10］Lounis N,Gevers T,Van Den Berg J,et al.Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model.Antimicrob Agents Chemother,2008,52(10):3568-3572.［11］Lounis N,Veziris N,Chauffour A,et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother, 2006,50(11):3543-3547.［12］Tibotec Pharmaceuticals Limited. Anti-bacterial activity, safety, and tolerability of TMC207 in patients with multi-drug resistant Mycobacterium tuberculosis (MDR-TB)［R/OL］. Bethesda （MD）:US National Library of Medicine. 2007［2010-05-05］. http://www.clinicaltrials.gov.ct.Show/NCT00449644?order=1.［13］Diacon AH,Pym A,Grobusch M,et al.The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med, 2009,360(23):2397-2405.［14］Churchyard GJ, Friedland G,Fielding K,et al. Opportunities afforded by new drugs for tuberculosis. Lancet Infect Dis, 2010, 10(6):368-369.［15］Leibert E, Rom WN. New drugs and regimens for treatment of TB. Expert Rev Anti Infect Ther, 2010,8(7):801-813. ［16］朱友生.抗结核药物研究进展. 中国防痨杂志,2007,29(4): 348-350.［17］黄海荣，于霞，姜广路，等. 利奈唑胺治疗耐多药结核病的初步评价.中国防痨杂志,2011,33(5): 275-279.［18］唐神结, 肖和平.广泛耐药结核病的现状与对策. 中华医学杂志,2011，91（5）: 355-358.［19］Amaral L, Boeree MJ,Gillespie SH,et al. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents, 2010, 35(6):524-526.［20］Amaral L, Molnar J. Therapy of XDR-TB with thioridazine a drug beyond patent protection but eligible for patent “as new use”. Recent Pat Antiinfect Drug Discov, 2010, 5(2):109-114.［21］Viveiros M, Martins M, Couto I, et al. Molecular tools for rapid identification and novel effective therapy against MDR-TB/XDR-TB infections. Expert Rev Anti Infect Ther, 2010, 8(4):465-480.［22］Amaral L,Martins M,Viveiros M. Phenothiazines as anti-multi-drug resistant tubercular agents. Infect Disord Drug Targets, 2007,7(3):257-265.［23］TB Alliance. Since its founding in 2000,TB Alliance has built the largest, most diverse tuberculosis drug pipeline in history［R/OL］.［2010-05-05］.http://www.tballiance.org/new/portfolio.php. |
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.
